Related Experiment Video
Updated: Aug 19, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Assisted Extraction with Cyclodextrins as a Way of Improving the Antidiabetic Activity of Actinidia Leaves
Szymon Sip1, Anna Gościniak1, Piotr Szulc2
1Department of Pharmacognosy, Faculty of Pharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806 Poznań, Poland.
Abstract:
Five varieties of Actinidia leaves (Geneva, Jumbo, Ken's Red, Kijivska Hibridna, and Sentyabraskaya) were analyzed. The profiles of active compounds were determined, namely quercetin, rutin, epicatechin, chlorogenic acid, and kaempferol, in the raw material. Suspecting that the raw material might prove important in the treatment of diabetes, the authors assessed the antioxidant activity and the ability to inhibit enzymes responsible for the development of diabetes (α-glucosidase and α-amylase). As a result of the conducted analysis, the Ken's Red variety was indicated as having the highest biological activity (DPPH IC50 = 0.332 ± 0.048; FRAP IC0.5 = 0.064 ± 0.005; α-glucosidase inhibition IC50 = 0.098 ± 0.007; α-amylase inhibition IC50 = 0.083 ± 0.004). In order to increase the efficiency of the extraction of active compounds from Ken's Red variety leaves, cyclodextrins (α-CD, β-CD, and γ-CD) were used as extraction process enhancers. The obtained results showed a significant increase in the contents of extracted active compounds. In addition, the type of CD used enhanced the extraction of selected compounds (quercetin, kaempferol, rutin, chlorogenic acid, and epicatechin. This study shows that the application of cyclodextrin-based extraction significantly improved the leaf activity of the Ken's Red variety (DPPH IC50 = 0.160 ± 0.019; FRAP IC0.5 = 0.008 ± 0.001; α-glucosidase inhibition IC50 = 0.040 ± 0.002; α-amylase inhibition IC50 = 0.012 ± 0.003).
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

